Carboplatin and etoposide in previously treated colorectal cancer patients

Tumori. 1995 Jan-Feb;81(1):36-8. doi: 10.1177/030089169508100108.

Abstract

Aims and background: Salvage treatment of advanced colorectal cancer patients has not been well defined as yet, and new potentially active drugs or combinations should be evaluated for these situations.

Methods: From February 1993 to September 1993, the combination of carboplatin (CBDCA) and etoposide (VP-16), both as 100 mg/m2 for three consecutive days, was administered to 17 colorectal cancer patients who had been previously subjected to FA-FU combination chemotherapy. The CBDCA + VP-16 treatment was repeated every 3 weeks. A total of 58 cycles was administered, and 16 patients were evaluable for response.

Results: There was no objective response, but 2 stable diseases and 14 progressive diseases were observed. Toxicity was mild, with no WHO 3-4 grade toxicity.

Conclusion: This combination chemotherapy was judged ineffective for pretreated colorectal cancer patients.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carboplatin / administration & dosage
  • Colorectal Neoplasms / drug therapy*
  • Etoposide / administration & dosage
  • Female
  • Humans
  • Male
  • Middle Aged
  • Salvage Therapy

Substances

  • Etoposide
  • Carboplatin